Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Bio-Thera Solutions has begun Phase 1 testing of BAT8013, an investigational CD25-targeting antibody-drug conjugate being evaluated in patients with advanced solid tumors. Representative image.
Pharma & Biotech

Can Bio-Thera’s BAT8013 turn regulatory T-cell depletion into a workable solid-tumor strategy?

Bio-Thera has dosed the first patient in BAT8013’s Phase 1 trial. See why safety, Treg selectivity and dose choice will decide its future.

Read More
Antix LLC targets retailers with Brandage tattoo-transfer adhesive bandages
Medical Devices & Diagnostics

Brandage targets children’s first-aid market with tattoo-transfer bandage design

Brandage takes tattoo-transfer adhesive bandages to ASD Market Week, testing whether playful wound care can win national retail distribution.

Read More
Beckman Coulter targets laboratory staffing pressure with DxU 1800 automation
Medical Devices & Diagnostics

How Beckman Coulter DxU 1800 combines urine chemistry and digital microscopy

Beckman Coulter launches DxU 1800 to automate urine chemistry and microscopy as laboratories face higher testing volumes and staffing pressure.

Read More
ALZpath and Alamar Biosciences are expanding their pTau217 collaboration to support the development of blood-based clinical diagnostics for Alzheimer’s disease, as laboratories pursue more accessible biomarker testing pathways. Representative image.
Medical Devices & Diagnostics

ALZpath just gave Alamar a bigger Alzheimer’s diagnostics role, but the regulatory test starts now

ALZpath expands its Alamar Biosciences deal into clinical diagnostics, opening a new path for pTau217 blood tests in Alzheimer’s disease.

Read More
A radiologist reviews AI-assisted chest CT scans as HOPPR expands developer access to medical imaging foundation models with its new chest CT narrative model. Representative image.
Medical Devices & Diagnostics

HOPPR’s chest CT model tackles radiology’s hardest AI test, but validation will decide what comes next

HOPPR adds a chest CT narrative model, widening developer access while leaving validation, regulation and workflow adoption as the key tests.

Read More
MolecuLightDX fluorescence imaging is being evaluated during revision knee surgery to help surgeons detect residual bacterial signals after standard debridement, although larger controlled studies are needed to confirm clinical benefits. Representative image.
Medical Devices & Diagnostics

MolecuLight study tests fluorescence-guided debridement in infected knee revision surgery

MolecuLightDX detected residual fluorescent bacterial signals after knee debridement, but larger trials must prove better infection outcomes.

Read More
Momentis Surgical expands Anovo as surgical robotics competition intensifies
Medical Devices & Diagnostics

Momentis Surgical Anovo FDA clearance expands robotic surgery to multiport procedures

Momentis Surgical wins FDA clearance for Anovo multiport surgery, widening its robotic platform while adoption and evidence remain key.

Read More
Synaptiq Therapeutics is advancing the acquired SYN-001 clinical programme toward a Phase IIb trial targeting neuropsychiatric symptoms associated with 22q11.2 deletion syndrome. Representative image.
Pharma & Biotech

What Synaptiq Therapeutics’ SYN-001 acquisition means for 22q11.2 deletion syndrome

Synaptiq Therapeutics acquires SYN-001 and plans a Phase IIb trial for neuropsychiatric symptoms in 22q11.2 deletion syndrome.

Read More
AnHorn Medicines has begun first-in-human testing of AH-008 as the biotechnology company investigates whether the experimental therapy could help prevent chemotherapy-induced peripheral neuropathy. Representative image.
Pharma & Biotech

AnHorn Medicines doses first participant in Phase 1 AH-008 CIPN prevention trial

AnHorn Medicines doses the first participant in a Phase 1 AH-008 study, opening a cautious clinical test of chemotherapy neuropathy prevention.

Read More
Novellia’s GLP-1 and Metabolic Health Registry aims to track weight outcomes, treatment persistence and coverage disruptions across complex patient journeys, addressing evidence gaps left by traditional healthcare datasets. Representative image.
Pharma & Biotech

Novellia’s GLP-1 registry found a surprising weight-loss pattern, but what does it really prove?

See how Novellia’s GLP-1 registry could sharpen real-world evidence while facing tests on validation, bias, privacy and payer use.

Read More